Home / Wiki / A / AI-Developed Drugs

AI-Developed Drugs

Technology and VendorsUpdated 16 Nov 2026

AI-developed drugs are medicine candidates in which artificial intelligence played a substantial part in choosing the biological target, designing the molecule or optimizing its properties. Methods from machine learning are used to predict protein structures, generate and rank candidate compounds, and select patients for trials. The aim is to shorten the early stages of research and development and to raise the low share of candidates that survive clinical testing.

The field is young. A number of such candidates have entered human trials, but whether they succeed more often in late-stage trials than conventionally discovered drugs has not yet been established, and regulators assess them under the same rules as any other medicine. As a theme in thematic investing it covers specialist biotechnology firms, their partnerships with large drug makers, and suppliers of computing and data. Returns depend on trial results and on intellectual property, which makes outcomes highly uneven.

Last updated 16 Nov 2026